Telix Pharmaceuticals Limited - Capital Markets Day - TELIX PHARMACEUTICALS LTD

Explicit Guidance:

• Revenue: Expected to reach approximately $1 billion USD for the current year, landing at the top end of maintained guidance.
• Revenue Forecast: Projected to reach $1.5 billion USD (approx. $2 billion AUD) in revenue next year (implied FY2026), driven by the addition of ITM revenue (~$300 million) and commercial growth.
• Growth Rates:
  • Precision medicine business to exceed 25% year-over-year (YoY) growth in the current year, with expectations to continue this trajectory.
  • ITM manufacturing business expected to grow at an 18% CAGR over the next five years (underpinned by long-term contracts running into the 2030s).
  • Potential addressable market for Lutetium-177 assets projected to rise from ~$300 million to $2.1 billion.
  • Potential addressable market for Actinium projected to reach $1.4 billion by 2034–2035.
• Margins: Gross margin for the precision medicine business is improving and currently at 65%; ITM currently operates at 40% margins with expected accretion as volume scales.
• Synergies: Approximately $50 million in synergies expected to be achieved within the first two years of combining Telex with ITM.
• R&D Spend: Estimated at 26% of sales, significantly below the 35% industry average for therapeutic-focused companies.
• Infrastructure Capex: Approximately $100 million per year planned investment to continue building and growing supply chain infrastructure (cyclotrons, radiation capabilities).

Business-Segment Outlook:

• Commercial Portfolio Expansion: Expect to have six FDA-approved products by this time next year (currently three), including a distinct de novo NDA submission for "Bypass" (Gallium-68 PSMA) and the anticipated approval of Zircax (Zirconium-89 CA9) in 2027.
• Geographic Expansion: Currently active in 22 countries with approved products; committed to expanding jurisdictional approvals for PixClara (Fluorine-18 FET) and other assets globally.
• Product Specifics:
  • PixClara: Expected to double U.S. volume and market penetration within one year; anticipated to drive "step change" in the market for brain cancer imaging and staging.
  • Bypass (Gallium-68): Regulatory readout awaited; potential to triple the volume of patients serviced by shifting diagnostic workflow to pre-biopsy; distinct market access strategy planned.
  • Zircax: Anticipated FDA approval in 2027 for clear cell renal cell carcinoma (CCRCC) imaging; expected to transform diagnosis and staging similar to the PSMA revolution.
  • Therapeutics:
    • 597 (Lutetium-177 PSMA small molecule): Phase 3 trials (PROSE) and dose-intensification trials (Optimal PSMA) targeting earlier disease stages (hormone-sensitive); readouts expected early next year.
    • 591 (Lutetium-177 PSMA antibody): Phase 3 global enrollment accelerating in the U.S. and China; two-dose, two-week schedule designed to integrate with standard of care.
    • 101 (Iodine-131 glioblastoma): Phase 3 IPAX-BRIGHT study planned; Phase 2 IPAX-T2 completed recruitment, awaiting data.
    • 250 (Lutetium-177 CA9): Phase 3 "Luteon" trial enrolling in Australia, Europe, and the U.S. for late-line renal cancer.
• ITM Integration: ITM acquisition brings a portfolio of ~100 therapeutics and ~50 companies as potential partners; ITM produces ~80% of the world's Lutetium and enables Actinium/Lead-212 production.
• Manufacturing Capacity: 45 global manufacturing sites handling radioactivity; new Actinium supply facility in Philadelphia under construction (first commercially available in the U.S.); Lead-212 production scaling up for rollout next year via RLS pharmacy network.

Market and Competitive Outlook:

• Industry Pivot: Market transformation shifting from diagnostic nuclear medicine (5% CAGR) to therapeutics; the future growth lies in the $100+ pipeline drugs coming behind the current two approved therapies.
• Supply Chain Dynamics: A "parallel race" between pipeline development and commercialization; success dependent on controlling supply chain infrastructure to guarantee patient delivery and avoid missed doses that damage clinician relationships.
• Differentiation: Telex views a vertically integrated commercial and supply model as a "durable competitive moat" and distinct advantage over peers who outsource critical manufacturing; no other company in radiopharma matches current infrastructure scale.
• Targeting Vectors: Company remains agnostic to targeting vectors (antibody, peptide, small molecule, amino acid) and is investing across the spectrum to capture value in urologic, neurologic, and musculoskeletal oncology.
• Market Share: Anticipates becoming the "shop front" and go-to commercial partner for the broader industry, supplying isotopes (Lutetium, Actinium) to big pharma and smaller biotechs while commercializing their own pipeline.

Macro / Industry Outlook:

• Timeline: The radiopharma sector is in a "boom" phase, with a strategic shift expected over the next decade toward therapeutics.
• Regulatory Environment: Recent interactions with the FDA (e.g., Zircax resubmission, Bypass strategy) have clarified requirements for biologics and novel combinations; while a steep learning curve exists for biologics, the company believes it is now "far ahead" in regulatory navigation.
• Economic Outlook: Operating leverage expected to improve significantly as the commercial team and supply chain costs are amortized across a growing portfolio of six+ products.
• Competition: The "wheat from chaff" separation expected in the next two years; competitors lacking infrastructure or late-stage pipelines are at risk, while Telex positions itself as a "global radiopharma powerhouse."

Strategic Initiatives:

• ITM Acquisition: Closing expected to accelerate pathway to therapeutics within six months; brings isotopes, clinical infrastructure, and a pipeline of 100 assets; expected to transform the company into a 2027 commercial year player rather than 2028.
• Regeneron Partnership: Collaboration focused on alpha-emitter assets (Actinium, Lead-212, Astatine) using Regeneron's antibody/minibody technology; dedicated facility in Traib (near Philadelphia) to serve as an innovation and clinical trial hub for alpha therapies.
• Manufacturing Expansion: Building a 2027 "multiplier effect" commercial capability; constructing Actinium supply facility in Philadelphia; scaling Lead-212 production; securing GMP licenses in Europe.
• M&A Strategy: Continued selective M&A focused on infrastructure, pipeline assets, and life-cycle management; open to opportunities that strengthen the three pillars (Commercial, Pipeline, Supply Chain).
• Product Lifecycle Management: Expansion of label indications and geographic approvals for existing assets (Gazelix, PixClara) to sustain growth; shifting from early-stage R&D to an earnings growth story starting in 2028.

Risks and Headwinds to Outlook:

• Regulatory Delays: Pending readouts for Bypass, Zircax resubmission, and Phase 3 trials (597, 591, Luteon, IPAX-BRIGHT); delays could impact revenue timing.
• Manufacturing Complexity: "Scale-up" from clinical to commercial (hundreds/thousands of doses) is technically difficult; missed doses in supply chain could damage clinician relationships.
• Market Adoption: Need for markets to internalize the value of the integrated supply chain and the shift to early-stage theranostics; potential resistance to shifting diagnostic paradigms (e.g., Gallium vs. Fluorine-18).
• Competition: Intense competition for limited manufacturing infrastructure (reactors, cyclotrons) and isotope supply; risk of commoditization if supply chains remain external.
• Clinical Outcomes: Dependence on Phase 3 readouts showing overall survival benefits (e.g., Luteon, IPAX-BRIGHT) to move therapies upstream in the treatment paradigm.
• Execution Risk: Integrating ITM and Regeneron assets while maintaining clinical trial timelines; risk of failing to achieve the stated $50M synergies.

Management Tone on the Future:

• Confidence Level: High confidence in the "boom" nature of the radiopharma sector and the company's unique "end-to-end" capability (discovery to delivery).
• Strategic Pivot: Strong belief that the "race" is now about commercialization and supply chain ownership; Telex is positioning itself as a partner of choice for the broader industry.
• Growth Narrative: Shift in focus from "clinical catalysts" to "multi-product, multi-jurisdictional commercial performance" with an anticipated transition to an earnings growth story by 2028.
• Capital Discipline: Emphasis on funding growth from operations ("self-powered") to avoid dilution; high confidence in generating capital to reinvest in the pipeline.
• Market Sentiment: Expresses excitement about the "step change" in capability with six products by next year and the "global domination" of medical standards through widespread patient access.

Miscellaneous:

• Q&A Highlights: Key Opinion Leaders (KOLs) emphasized the superiority of Gallium-68 over Fluorine-18 in sensitivity/specificity (92% vs 65% accuracy in staging) and the potential for PSMA PET to reduce unnecessary biopsies by up to 50%.
• Clinical Data: Early data from Optimal PSMA shows dose-intensification (3 doses in 2 weeks) yields deep responses (PSA <0.3) even in high-volume disease; 597 demonstrates lower kidney/salivary dose compared to competitors (Pluvicto/INT).
• Operational Efficiency: Telex reports faster launch times (2 weeks for PIX-Clar vs 4 months for Eleusix) due to integrated supply chain, avoiding third-party delays.
• Talent: Acquired talent from ITM and Regeneron collaborations viewed as a critical asset; race for talent in radiopharma is intense.